or Try an Advanced Search...

    Advanced Solid Tumors Stocks List

    Symbol Grade Name % Change
    ELEV D Elevation Oncology, Inc. -0.30
    CASI D CASI Pharmaceuticals, Inc. -2.86
    IMRX F Immuneering Corporation -0.47
    HOWL F Werewolf Therapeutics, Inc. 6.74
    RLAY F Relay Therapeutics, Inc. 2.37
    CRDF F Cardiff Oncology, Inc. -2.00
    CLRB F Cellectar Biosciences, Inc. 0.00
    ADCT F ADC Therapeutics SA 2.58
    SLRX F Salarius Pharmaceuticals, Inc. -6.16
    PPBT F Purple Biotech Ltd. -13.78
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research
    Related Stock Lists: Solid Tumors Cancer Clinical Medicine Medicine Biotechnology Oncology Antineoplastic Drugs Biopharmaceutical Cancer Treatment Life Sciences Treatment Of Cancer Chemotherapy Drugs Health Sciences Leukemia Lymphoma Metastatic Solid Tumors Ovarian Cancer Pharmaceutical Prostate Cancer

    Related ETFs - A few ETFs which own one or more of the above listed Advanced Solid Tumors stocks.

    Symbol Grade Name Weight
    TXSS A Texas Small Cap Equity Index ETF 0.04
    RFLR B Innovator U.S. Small Cap Power Buffer ETF - September Innovator U.S. Small Cap Managed Floor ETF 0.02
    IWC B iShares Microcap ETF 0.01
    DFAC A Dimensional U.S. Core Equity 2 ETF 0.0
    ISCB A iShares Morningstar Small-Cap ETF 0.0
    View all Advanced Solid Tumors ETFs...
    Compare ETFs
    Compare RFLR to ISCB Compare TXSS to IWC Compare TXSS to RFLR

        Advanced Solid Tumors Stocks Recent News

        Date Stock Title
        Nov 20 RLAY Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 20 HOWL Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
        Nov 19 RLAY Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround
        Nov 19 CRDF Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
        Nov 19 CLRB Q3 2024 Cellectar Biosciences Inc Earnings Call
        Nov 18 CLRB Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
        Nov 18 CLRB Cellectar Biosciences GAAP EPS of -$0.40 misses by $0.03
        Nov 18 CLRB Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
        Nov 18 CLRB Earnings Scheduled For November 18, 2024
        Nov 17 CASI CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
        Related Industries: Biotechnology Diagnostics & Research
        Related Stock Lists: Autoimmune Disease Biotechnology Cancer Clinical Pharmacology Clinical Research Clinical Trial Life Sciences Lymphoma Ovarian Cancer Solid Tumors Treatment Of Cancer Treatment Of Ovarian Cancer
        Advanced Solid Tumors

        Advanced solid tumors are cancerous tumors that have spread beyond the original site of the tumor and have become more difficult to treat. These tumors are often referred to as metastatic or stage IV tumors. Advanced solid tumors can affect any part of the body and can be caused by a variety of different types of cancer. Treatment options for advanced solid tumors may include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, and/or clinical trials.

        Browse All Tags